About this trial
Prognostic Value Enhancement Of Sequential Organ Failure Assessment )SOFA( Score by Neutrophil-Lymphocyte Ratio and Red Cell Distribution Width in Cardiogenic Shock Patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients aged ≥18 years
Disqualifiers
Septic, hypovolemic, or obstructive shock Active infection or chronic inflammatory disease Hematological disorders affecting leukocytes or red blood cells Malignancy Chronic liver disease Recent blood transfusion Patients on immunosuppressive or steroid therapy
Trial population
A total of 150 patients will be recruited. The sample size was determined based on the ability to evaluate the prognostic value of neutrophil-lymphocyte ratio and red cell distribution width in patients with cardiogenic shock. Based on previous studies, the expected in-hospital mortality among cardiogenic shock patients is approximately 40-50%. With a confidence level of 95% and a statistical power of 80%, a minimum sample size of 90 patients was required. To account for possible missing data or incomplete records, the sample size was increased by 10%, resulting in a final sample size of 150 patients.
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Number of patients with Higher NLR and RDW values who died With Cardiogenic Shock
Occurrence of death from any cause during hospitalization, assessed in relation to baseline neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width (RDW).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: